Levodopa/carbidopa/entacapone

Drug Profile

Levodopa/carbidopa/entacapone

Alternative Names: Carbidopa/entacapone/levodopa; ELC-200; Entacapone/levodopa/carbidopa; Stalevo; Stavelo

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Orion
  • Developer Novartis; Orion
  • Class Antiparkinsonians; Catecholamines; Catechols; Hydrazines; Nitriles; Small molecules
  • Mechanism of Action Catechol-O-methyltransferase inhibitors; Decarboxylase inhibitors; Dopamine receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Parkinson's disease

Most Recent Events

  • 16 Aug 2016 Launched for Parkinson's disease in Chile (PO) before August 2016
  • 06 Jul 2016 Launched for Parkinson's disease in Turkey (PO) before July 2016
  • 19 May 2016 Launched for Parkinson's disease in Israel (PO) before May 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top